FDA's iPSP: The Pediatric Plan Is Due at End of Phase 2, Not at BLA

Under the Pediatric Research Equity Act (21 U.S.C. § 355c), most applications for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration must include an assessment of safety and effectiveness in pediatric patients — unless FDA has waived, deferred, or found the requirement inapplicable. Sponsors who treat that as a BLA-time deliverable are already late. FDA's guidance sets the Initial Pediatric Study Plan (iPSP) due within 60 calendar days of the End-of-Phase-2 meeting, and an application that reaches FDA without an agreed iPSP is exposed to a refuse-to-file action before anyone reviews the science.

What PREA actually requires

PREA is a statutory requirement, not a guidance preference: an application for a new active ingredient (including a new salt or new fixed combination), a new indication, a new dosage form, a new dosing regimen, or a new route of administration must include data assessing the product's safety and effectiveness in the pediatric population relevant to that indication. The assessment requirement attaches to the IND-stage development program long before it becomes a marketing-application deliverable — which is exactly why the planning window sponsors actually have is narrower than the BLA timeline makes it look.

Waiver, deferral, or inapplicable — three different outcomes

Not every PREA-triggering application ends with new pediatric trials on the critical path. FDA can grant a full or partial waiver — for example, where the disease or condition does not occur in the pediatric population, where necessary studies are highly impracticable, or where there is evidence the product would be ineffective or unsafe in some or all pediatric age groups. A deferral is a different outcome entirely: the pediatric studies are still required, but FDA allows them to proceed after approval, typically because the adult program needs to establish safety and effectiveness first. Treating these as interchangeable is a common planning error — a waiver removes the requirement, a deferral only reschedules it, and the iPSP has to state which one the sponsor is requesting and why.

• Waiver. FDA agrees no pediatric studies are required for some or all pediatric subpopulations — the requirement is removed, not postponed.
• Deferral. Pediatric studies remain required but can be completed after marketing approval, tracked as a postmarketing requirement against its own clock.
• Inapplicable — orphan designation. PREA's study requirement generally does not apply to a drug or indication that holds orphan designation.
• The oncology exception to the exception. The RACE for Children Act removed the orphan exemption for cancer drugs directed at a molecular target relevant to pediatric cancer — orphan status alone no longer clears those programs of PREA.

The iPSP is not a BLA attachment. It is a negotiation that has to be settled while the Phase 3 program is still being designed — because FDA's comments on it can change what that program needs to capture. Why the End-of-Phase-2 clock matters

What happens if you miss the clock

FDA's guidance on pediatric study plans states that failure to include an FDA-agreed iPSP — or an outstanding deferral or waiver request — with the marketing application could result in a refuse-to-file action. That risk sits upstream of substantive review entirely: a refuse-to-file decision means the application doesn't get evaluated on its merits until the pediatric planning gap is closed. The iPSP also isn't a one-time filing. As the adult development program evolves — a new endpoint, a changed population, an added indication — the plan needs amending, and the version FDA actually agreed to is the one that has to be on file when the marketing application goes in. Coordinating that against an End-of-Phase-2 meeting strategy built around the adult program alone, without the pediatric clock running in parallel, is where most of the exposure comes from.

None of this is exotic, but it is easy to under-resource, because the iPSP looks like a paperwork requirement until the refuse-to-file letter arrives. The procedural question — when the plan is due, and whether it is agreed — is PREA's alone. The scientific question of how much pediatric evidence an approved adult indication actually needs to support is a separate matter, and ICH E11A's extrapolation framework is where that gets decided; a well-built iPSP is often the document where an extrapolation strategy gets proposed to FDA in the first place. Building both into a single pediatric regulatory strategy from EOP2 onward is what keeps the marketing application from being the moment the gap gets discovered.